<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912193</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1699</org_study_id>
    <nct_id>NCT04912193</nct_id>
  </id_info>
  <brief_title>Antithrombin III and Post-liver Transplantation Acute Kidney Injury</brief_title>
  <official_title>Low Preoperative Antithrombin III Level is Associated With Postoperative Acute Kidney Injury After Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reno-protective effect of Antithrombin III (ATIII) has been well-studied in various&#xD;
      animal studies; however, little is known about the effect of ATIII on kidney function in&#xD;
      patients undergoing liver transplantation (LT). This study aimed to determine the association&#xD;
      between preoperative ATIII level and postoperative acute kidney injury (AKI) after LT&#xD;
      (post-LT AKI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2010</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>acute kidney injury</measure>
    <time_frame>postoperative 7 day</time_frame>
    <description>serum creatinine &gt;0.3 mg/dL within POD 2 or increase by &gt;1.5 times within POD 7 according to the criteria set by the Kidney Disease: Improving Global Outcomes (KDIGO) classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>chronic kidney disease</measure>
    <time_frame>postoperative 3 months</time_frame>
    <description>glomerular filtration rate less than 60 mL∙min-1∙1.73m-2 on two consecutive occasions at least 3 months apart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>early allograft dysfucion</measure>
    <time_frame>postoperative 7 day</time_frame>
    <description>at least one of the following: total bilirubin ≥10 mg/dL on postoperative day (POD) 7, prothrombin time (INR) ≥1.6 on POD 7, and alanine or aspartate aminotransferases &gt;2000 IU/L within POD 7</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2395</enrollment>
  <condition>Liver Transplantation and Antithrombin</condition>
  <arm_group>
    <arm_group_label>antithrombin III &lt; 50 %</arm_group_label>
    <description>preoperative antithrombin III levels &lt;50%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antithrombin III ≥ 50 %</arm_group_label>
    <description>preoperative antithrombin III levels ≥ 50 %</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombin III</intervention_name>
    <description>In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.</description>
    <arm_group_label>antithrombin III &lt; 50 %</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who underwent either living- or deceased-donor LT (LDLT, DDLT) from January 2010&#xD;
        to January 2018 in Asan Medical Center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients who underwent either living- or deceased-donor LT (LDLT, DDLT) from January&#xD;
             2010 to January 2018&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who underwent re-transplantation&#xD;
&#xD;
          -  patients who were previously diagnosed with end-stage renal disease or Chronic kidney&#xD;
             disease&#xD;
&#xD;
          -  patients who were being treated with continuous renal replacement therapy&#xD;
&#xD;
          -  preoperative or postoperative Antithrombin III levels were not available&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05507</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost. 2016 Apr;115(4):712-28. doi: 10.1160/TH15-08-0687. Epub 2015 Dec 17. Review.</citation>
    <PMID>26676884</PMID>
  </reference>
  <reference>
    <citation>Wu R, Kong Y, Yin J, Liang R, Lu Z, Wang N, Zhao Q, Zhou Y, Yan C, Wang F, Liang M. Antithrombin Ⅲ is a Novel Predictor for Contrast Induced Nephropathy After Coronary Angiography. Kidney Blood Press Res. 2018;43(1):170-180. doi: 10.1159/000487499. Epub 2018 Feb 16.</citation>
    <PMID>29466798</PMID>
  </reference>
  <reference>
    <citation>Lu Z, Cheng D, Yin J, Wu R, Zhang G, Zhao Q, Wang N, Wang F, Liang M. Antithrombin III Protects Against Contrast-Induced Nephropathy. EBioMedicine. 2017 Mar;17:101-107. doi: 10.1016/j.ebiom.2017.02.009. Epub 2017 Feb 12.</citation>
    <PMID>28219627</PMID>
  </reference>
  <results_reference>
    <citation>Wang F, Zhang G, Lu Z, Geurts AM, Usa K, Jacob HJ, Cowley AW, Wang N, Liang M. Antithrombin III/SerpinC1 insufficiency exacerbates renal ischemia/reperfusion injury. Kidney Int. 2015 Oct;88(4):796-803. doi: 10.1038/ki.2015.176. Epub 2015 Jun 24.</citation>
    <PMID>26108065</PMID>
  </results_reference>
  <results_reference>
    <citation>Yin J, Wang F, Kong Y, Wu R, Zhang G, Wang N, Wang L, Lu Z, Liang M. Antithrombin III prevents progression of chronic kidney disease following experimental ischaemic-reperfusion injury. J Cell Mol Med. 2017 Dec;21(12):3506-3514. doi: 10.1111/jcmm.13261. Epub 2017 Aug 2.</citation>
    <PMID>28767184</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>May 30, 2021</last_update_submitted>
  <last_update_submitted_qc>May 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Kyoung-Sun Kim</investigator_full_name>
    <investigator_title>Senior Clinical Fellow</investigator_title>
  </responsible_party>
  <keyword>acute kidney injury</keyword>
  <keyword>antithrombins</keyword>
  <keyword>liver transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

